The Controversial Role of Serum Uric Acid in Cardiovascular Diseases

Yıl 2017, Cilt: 3 Sayı: 3, 54 - 56, 01.07.2017

Alexander E Berezin

https://doi.org/10.5455/umj.20170608022350

Öz

Previous clinical, observation and epidemiologic studies have demonstrated strong association between serum uric acid SUA and cardiovascular disease hypertension, heart failure, asymptomatic atherosclerosis , metabolic states abdominal obesity, diabetes mellitus, metabolic syndrome, insulin resistance and kidney disease. There is a large body of evidence regarding the role of SUA as predictor of CV events and CV mortality in general population and individuals with established CV disease and metabolic diseases. However, SUA may exhibit protective effects on endothelium and vasculature as well as attenuate endogenous repair system through mobbing and differentiation of cell precursors. Although SUA lowering drugs are widely used in patients with symptomatic hyperuricemia and gout beyond their etiologies, there is no agreement of SUA below target level 6.0 mg/dL in asymptomatic individuals with kidney injury and CV disease and data of ones are sufficiently limited. The short communication is depicted on the controversial role of SUA as primary cell toxicity agent and secondary cell protector against hypoxia, ischemia and apoptosis.

Anahtar Kelimeler

Serum uric acid, cardiovascular disease, metabolic states, outcomes, biomarker

Kaynakça

• 1.Scheepers LEJM, Boonen A, Dagnelie PC, Schram MT, van der Kallen CJH, Henry RMA, et al. Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht study. J Hypertens. 2017..
• 2.Lai CL, Xing JP, Liu XH, Qi J, Zhao JQ, Ji YR, et al. Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hyperten sion Patients. Chin Med J (Engl). 2017;130(11):1296-1302.
• 3.Magnoni M, Berteotti M, Ceriotti F, Mallia V, Vergani V, Peretto G, et al. Serum uric acid on admission predicts inhospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017. pii: S0167-5273(17)30712-X.
• 4.Berezin AE. Prognostication in different heart failure phenotypes: the role of circulating biomarkers. Journal of Circulating Biomarkers. 2016, 5:01.
• 5.Berezin AE, Kremzer AA. Serum uric acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiology Research and Practice. 2013, Article ID 129369,7p.
• 6.Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA, Zulli A, et al. The utility of biomarker risk prediction score in patients with chronic heart failure. Int J ClinExp Med 2015;8(10):18255-64.
• 7.Lai S, Mariotti A, Coppola B, Lai C, Aceto P, DimkoMet al. Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease--preliminary data. Eur Rev Med Pharmacol Sci. 2014;18(7):1010-7.
• 8.Krajcoviechova A, Tremblay J, Wohlfahrt P, Bruthans J, Tahir MR, Hamet P, et al. The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. Am J Hypertens. 2016;29(12):1335-1342.
• 9.Geraci G, Mulè G, Morreale M, Cusumano C, Castiglia A, et al. Association between uric acid and renal function in hypertensive patients: which role for systemic vascular involvement?J Am SocHypertens. 2016;10(7):559-569.
• 10.Bharti S, Bharti B. Serum Uric Acid and Childhood Hypertension: Association to Causation to Prevention. Am J Hypertens. 2017.
• 11.Berezin AE. Biological markers of cardiovascular diseases. Part 4. Diagnostic and prognostic value of biological markers at risk stratification among patients with heart failure. LAMBERT Academic Publishing GmbH, Moskow, 2015-329 p.
• 12.Hsieh CH, Lin JD, Wu CZ, Hsu CH, Pei D, Liang YJ, et al. Is lower uric acid level better? A combined cross-sectional and longitudinal study in the elderly. Endocrine. 2014;47 (3):806-15.
• 13.Wijnands JM, Houben AJ, Muris DM, Boonen A, Schram MT, Sep SJ, et al.Uric acid and skin microvascular function: the Maastricht study.J Hypertens. 2015; 33(8):1651-7.
• 14.Berezin AE, Kremzer AA. Analysis of Various Subsets of Circulating Mononuclear Cells in Asymptomatic Coronary Artery Disease. J. Clin. Med. 2013; 2: 32-44.
• 15.Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neuro oncol. 2013; 113, 1–11.
• 16.Berezin AE. Microparticles in Chronic Heart Failure. Advances in Clinical Chemistry / 1st Edition. Serial Editors: Gregory S. Makowski 2017; Vol. 79, 1-252 p.
• 17.Berezin AE, Kremzer AA, Berezina TA, MartovitskayaYuV. The pattern of circulating microparticles in patients with diabetes mellitus with asymptomatic atherosclerosis. ActaClinicaBelgica: International Journal of Clinical and Laboratory Medicine. 2016; 71 (1):38-45.
• 18.Berezin AE. Biomarkers for cardiovascular risk in diabetic patients. Heart. 2016;102:1939-1941.
• 19.Berezin AE, Kremzer AA, Martovitskaya YV, Samura TA, Berezina TA. Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients. J CardiovascThorac Res, 2014;6(3):153-62.